Stock Market Reviews

VKTX (Viking Therapeutics, Inc.) News

Get the latest news, insights, and market updates on VKTX (Viking Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
  Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?
  Nov 7, 2025 - $VKTX
• Jim Cramer Recommends Eli Lilly Over Viking Therapeutics
  Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]
  Nov 6, 2025 - $VKTX
• Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in a poster presentation at ObesityWeek® 2025, the annual meeting of The Obesity Society. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors be
  Nov 6, 2025 - $VKTX
• Here's Why Shares in Viking Therapeutics Shot Higher in October
  Three factors took Viking's shares higher in the month.
  Nov 5, 2025 - $VKTX
• Viking Therapeutics to Participate at Upcoming Investor Conferences
  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences.
  Nov 4, 2025 - $VKTX
• Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera
  The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential milestone payments.
  Nov 4, 2025 - $VKTX
• Prediction: The Next Eli Lilly Might Already Be Trading Under $50
  Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
  Nov 3, 2025 - $VKTX
• Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
  The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
  Nov 3, 2025 - $VKTX
• Viking Therapeutics (VKTX): Assessing Valuation After Shares Jump 28% in the Past Month
  Viking Therapeutics (VKTX) has captured investor attention with its recent stock movement, delivering a 28% gain over the past month. This comes as traders revisit the company’s ongoing expansion in the biotech sector, considering recent trends alongside long-term performance. See our latest analysis for Viking Therapeutics. Viking Therapeutics’ share price has rebounded impressively, chalking up a 28% gain over the last month, as investors warm to biotech names and fresh developments spark...
  Nov 2, 2025 - $VKTX
• Should You Buy Viking Therapeutics Before Nov. 5?
  Viking's stock surged in one trading session after a positive clinical trial report last year.
  Nov 2, 2025 - $VKTX